Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

Katherine Francis; Val Gebski; Sarah Lord; Michael Friedlander; Eric Pujade-Lauraine; Chee Khoon Lee

doi:10.1016/j.ejca.2021.02.006

Journal articles

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

Katherine Francis Val Gebski Sarah Lord Michael Friedlander Eric Pujade-Lauraine ^{1, 2} Chee Khoon Lee

1 Hôpital Hôtel-Dieu [Paris]

2 UP - Université de Paris

Document type :

Journal articles

Domain :

Life Sciences [q-bio]

Complete list of metadata

https://hal-univ-paris.archives-ouvertes.fr/hal-03236358
Contributor : Hal Paris Diderot <>
Submitted on : Wednesday, May 26, 2021 - 11:17:32 AM
Last modification on : Wednesday, June 2, 2021 - 4:26:04 PM

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

Identifiers

Collections

Citation

Export

Metrics

7

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

Identifiers

Collections

Citation

Export

Share

Metrics

7